Select Bibliography

Filter by any of these (after searching):

ACOSOG-Z1031

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 21 items

Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).

Anurag, Meenakshi , Zhu, Mayanne , Huang, Chen , Vasaikar, Suhas ... - - J. Natl. Cancer Inst. - 2020

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer

Ellis, M. J. , Buzdar, A. U. , Unzeitig, G. W. , Esserman, L. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary - Primary - Breast - ACOSOG-Z1031

Whole-genome analysis informs breast cancer response to aromatase inhibition

Ellis, M. J. , Ding, L. , Shen, D. , Luo, J. Q. , Suman, V. J. ... - - Nature - 2012

Manuscript - Secondary-not-in-original - Comprehensive - PPP - ACOSOG-Z1031

Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%

Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012

Abstract - Primary - Primary - Breast - ACOSOG-Z1031B

Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders

Ellis, M. , Luo, J. , Tao, Y. , Hoog, J. , Snider, J. , DeSchryver, K. ... - SABCS - Cancer Research - 2009

Abstract - Secondary - Primary - Correl Sci NOS - ACOSOG-Z1031

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy ... - - J. Clin. Oncol - 2017

Manuscript - Secondary - Primary - Breast - ACOSOG-Z1031B

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy , Lin, Li ... - - J. Clin. Oncol. - 2011

Manuscript - Primary - Primary - Breast - ACOSOG-Z1031

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

Ellis, Matthew J , Lin, Li , Crowder, Robert , Tao, Yu , Hoog, Jeremy ... - - Breast Cancer Res Treat - 2010

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

Freedman, Rachel A. , Foster, Jared C. , Seisler, Drew K. ... - - J. Clin. Oncol - 2017

Manuscript - Primary - Primary - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527

Freedman, Rachel A , Seisler, Drew K. , Foster, Jared C. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Primary - Primary - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Haricharan, Svasti , Punturi, Nindo , Singh, Purba ... - - Cancer Discov - 2017

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

Local-regional recurrence (LRR) following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer versus chemotherapy.

Hunt, Kelly K. , Suman, Vera J. , Leitch, Ann M. , Unzeitig, Gary ... - SSO - Ann Surg Oncol - 2020

Abstract - Secondary - Primary - Breast - ACOSOG-Z1031

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer

Lei, Jonathan T. , Shao, Jieya , Zhang, Jin , Iglesia, Michael ... - - Cell Rep - 2018

Manuscript - Secondary - Primary - Correl Sci NOS - ACOSOG-Z1031

An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors

Luo, Jingqin , Liu, Shuzhen , Leung, Samuel , Gru, Alejandro A. ... - - J Mol Diagn - 2017

Manuscript - Secondary - Primary - Correl Sci NOS - ACOSOG-Z1031

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

Miller, Christopher A. , Gindin, Yevgeniy , Lu, Charles ... - - Nat Commun - 2016

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor positive breast cancer

Olson, J. A., Jr , Babiera, G. V. , Unzeitig, G. , Marcom, P. K. ... - ASCO Breast - Breast Cancer Symposium - 2010

Abstract - Primary - Primary - Breast - ACOSOG-Z1031

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Punturi, Nindo B. , Seker, Sinem , Devarakonda, Vaishnavi ... - - Nat Commun - 2021

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

Validation of the Preoperative Endocrine Prognostic Index in the ACOSOG (Alliance) Z1031 Neoadjuvant Aromatase Inhibitor Trial

Sanati, Souzan , Suman, Vera J. , Goncalves, R. , DeSchryver, K. ... - SABCS - Cancer Res. - 2015

Abstract - Secondary - Primary - Breast - ACOSOG-Z1031B

Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031).

Suman, Vera J , Du, Lili , Hoskin, Tanya , Anurag, Meenakshi ... - - Clin Cancer Res - 2022

Manuscript - Secondary-not-in-original - Primary - Breast - A151701 , ACOSOG-Z1031

Evaluation of the sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis. (Alliance)

Symmans, W. Fraser , Du, Lili , Hoskin, Tanya , Anurag, Meenakshi ... - ASCO - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

Age, Race, BMI and Pathologic Complete Response Following Neoadjuvant Chemotherapy: An Analysis of Four Alliance Clinical Trials

Warner, Erica T. , Ballman, Karla V. , Strand, Carrie ... - ASCO Breast - J. Clin. Oncol. - 2015

Abstract - Primary - Primary - Disparities - A151426 , ACOSOG-Z1031 , ACOSOG-Z1041 , CALGB-40601 , CALGB-40603